Brazil – Class II Medical Devices – New Resolution
A new Resolution of the Collegiate Board of Directors (RDC No. 423/2020) has been published by Brazil’s National Agency of Health Surveillance (ANVISA). This new Resolution announces the elimination of the ‘Cadastro’ pathway regarding the registration of medical devices (Class II) and IVDs, substituting it with a notification registration system.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

MEDICAL DEVICES LEGAL FRAMEWORK IN BRAZIL

Medical devices placed in the Brazilian market must be registered at Brazil’s National Agency of Health Surveillance (ANVISA), in accordance with the Brazilian Resolution RDC. No. 185. Manufacturers or importers of such products need to submit to ANVISA all the documents required for their registration as well as for their alteration, revalidation or cancellation. After evaluating all the documentation for registration, alteration, revalidation or cancellation, ANVISA publishes its decision on the Brazilian Official Gazette (DOU).

According to the risk they represent to consumers, patients, operators or third parties involved, medical products are classified as Class I, II, III or IV. In case of doubts in the classification, ANVISA is the one classifying the medical device.

Until recently, Class II medical devices were subject to a short registration process called ‘Cadastro’ (pre-market approval). Manufacturers of Class II medical devices (and some Class I) were requested to provide technical dossiers, labelling materials and proposed indications of use (IFU) documents to their Brazilian Registration Holder (BRH) representative in the country.

NEW RESOLUTION ON MEDICAL DEVICES CLASS II

According to the new Resolution published in September 2020, as it happens with Class I medical devices, Class II devices only require a formal notification (‘Notificação’) and no longer need an approval by ANVISA before entering the market. This notification shall be done using a special form available at ANVISA’s website. Now, manufacturers do not need to submit a technical dossier but should have these documentation available upon request (in case of an inspection by ANVISA). The main goal of the new Resolution is to help ANVISA to focus on high-risk medical products.

IVDs (Class I and II) may now also enter the Brazilian market via the notification pathway.

Class II medical devices that are already registered in ANVISA do not require a re-validation (except if changes are requested).

References:

  1. Resolução da Diretoria Colegiada – RDC Nº 423, de 16 se Setembro 2020. Available at: https://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?data=18/09/2020&jornal=515&pagina=110&totalArquivos=139
  2. Ministério da Saúde, Agência Nacional de Vigilância Sanitária (ANVISA) – Resolution RDC No. 185, of October 22nd, 2001. Available at: https://www.emergobyul.com/sites/default/files/file/rdc_185_2001_classification_and_registration_requirements_of_medical_products_0.pdf
  3. Ministério da Saúde, Agência Nacional de Vigilância Sanitária (ANVISA) – Resolução da Diretoria Colegiada – RDC Nº 270, de 28 de Fevereiro de 2019. Available at: http://rapassarini.com.br/wp-content/uploads/2019/03/RESOLUC%CC%A7A%CC%83O-DA-DIRETORIA-COLEGIADA-RDC-N%C2%BA-270-DE-28-DE-FEVEREIRO-DE-2019-Dia%CC%81rio-Oficial-da-Unia%CC%83o-Imprensa-Nacional.pdf
  4. Ministério da Saúde, Agência Nacional de Vigilância Sanitária (ANVISA) – Resolução da Diretoria Colegiada – RDC Nº 27, de 21 de Junho de 2011. Available at: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2011/rdc0027_21_06_2011.pdf

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »